Почетна › Колоректален карцином › Тексас
Клинички испитувања за Колоректален карцином во Тексас
145 студии за Колоректален карцином бараат учесници на локации во Тексас.
Градови во Тексас
- Houston102 студии
- San Antonio46 студии
- Dallas33 студии
- Austin19 студии
- Irving13 студии
- Tyler8 студии
- Fort Worth7 студии
- Killeen6 студии
- League City6 студии
- Abilene5 студии
- The Woodlands5 студии
- Round Rock3 студии
- Lewisville3 студии
- Amarillo3 студии
- Arlington3 студии
Официјален текст на студијата (англиски)
AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors
- NEXT Oncology, Irving
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT07454642A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer
- START Dallas Fort Worth, Fort Worth
- The University of Texas MD Anderson Cancer Center, Houston
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT07659795Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
- MD Anderson Cancer Center, Houston
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 5.10.2026 · NCT07411599A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
- Texas Oncology - Abilene - Antilley Road /ID# 280120, Abilene
- The University of Texas MD Anderson Cancer Center /ID# 279865, Houston
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT07525206A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- NEXT Austin, Austin
- START Center for Clinical Research, Fort Worth
- University of Texas MD Anderson Cancer Center, Houston
- и уште 1
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06270706The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- New Experimental Therapeutics - NEXT Oncology, Austin
- Texas Oncology, Bedford
- UT Southwest Simmons Cancer Center, Dallas
- и уште 2
Се регрутираФаза 1/2
Возраст 12 и постари · Сите полови · Ажурирано 2.10.2026 · NCT04585750A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 2.10.2026 · NCT06760819Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- The Don and Sybil Harrington Cancer Center, Amarillo
- UT MD Anderson Cancer Center, Houston
- Audie L Murphy VA Hospital, San Antonio
Се регрутираНабљудувачка студијаДобредојдени се здрави волонтери
Возраст од 40 до 75 · Сите полови · Ажурирано 2.10.2026 · NCT05334069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #46, Austin
- Exelixis Clinical Site #89, Dallas
- Exelixis Clinical Site #73, Irving
- и уште 2
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT05176483177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- MD Anderson Cancer Center, Houston
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT07189871Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- SCRI at Mary Crowley, Dallas
- University of Texas Southwestern Medical Center, Dallas
- The University of Texas MD Anderson Cancer Center, Houston
- и уште 1
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 1.10.2026 · NCT06625775Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
- The Methodist Hospital Research Institute, Houston
- The University of Texas MD Anderson Cancer Center, Houston
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT06324357A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 5, Houston
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 30.9.2026 · NCT07085091A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
- NEXT Dallas, Irving
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT07578571A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
- Research Site, Houston
- Research Site, Round Rock
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT05877599Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial
- UT MD Anderson Cancer Center, Houston
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 29.9.2026 · NCT07551596Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Texas Oncology - West Texas, Abilene
- Texas Oncology - West Texas, Amarillo
- Texas Oncology - Gulf Coast, Beaumont
- и уште 27
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT07222800Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)
- MD Anderson Cancer Center, GI Medical Oncology Dept, Houston
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT05482893A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
- Texas Oncology - Austin Midtown /ID# 271354, Austin
- Texas Oncology - Deke Slayton Cancer Center /ID# 271355, Webster
Се регрутираФаза 2
Возраст 18 и постари · Сите полови · Ажурирано 28.9.2026 · NCT06820463A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
- University of Texas MD Anderson Cancer Center ( Site 0316), Houston
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06428409A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
- Texas Oncology West Texas, Abilene
- Parkland Health and Hospital System, Dallas
- Texas Oncology DFW, Dallas
- и уште 6
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06750094A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors
- GSK Investigational Site, Dallas
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT07277270A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
- MD Anderson Cancer Center, Houston
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT05379595Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
- Research Site, Dallas
- Research Site, Galveston
- Research Site, Houston
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06218914A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
- Texas Oncology West Texas, Abilene
- Texas Oncology DFW, Dallas
- UT Southwestern, Dallas
- и уште 4
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06662786A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
- MD Anderson Cancer Center, Houston
- START San Antonio, San Antonio
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 25.9.2026 · NCT06004245Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Baylor, Scott and White Research Institute, Dallas
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 24.9.2026 · NCT06047379Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
- и уште 2
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 24.9.2026 · NCT05863195Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
- UT MD Anderson Cancer Center, Houston
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT06102902A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Texas Oncology Dallas Fort Worth West (DFWW) - Arlington Cancer Center North, Arlington
- Texas Oncology, PA, Austin
- Baylor College of Medicine Medical Center, Houston
- и уште 1
Се регрутираФаза 2/3
Возраст 18 и постари · Сите полови · Ажурирано 23.9.2026 · NCT07221357Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
- Research Site, Houston
Се регрутираФаза 2
Возраст од 18 до 130 · Сите полови · Ажурирано 23.9.2026 · NCT05489211A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Texas Oncology - DFW (Sammons CC), Dallas
- MD Anderson Cancer Center, Houston
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07114601A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Texas Oncology - DFW (Sammons CC), Dallas
- Baylor College of Medicine, Houston
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT07213791Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Baylor College of Medicine, Houston
- The University of Texas MD Anderson Cancer Center, Houston
- NEXT Oncology Dallas, Irving
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06445062Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- MD Anderson, Houston
- NEXT Dallas, Irving
- NEXT Oncology San Antonio, San Antonio
- и уште 1
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 22.9.2026 · NCT06128551A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer
- NEXT Houston, Houston
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 21.9.2026 · NCT07693751A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- The University of Texas MD Anderson Cancer Center - Texas Medical Center, Houston
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 21.9.2026 · NCT07629960Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- NEXT - Dallas, Dallas
- NEXT, San Antonio
- START - San Antonio, San Antonio
Се регрутираФаза 1
Возраст 18 и постари · Сите полови · Ажурирано 17.9.2026 · NCT07349537Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
- MD Anderson Cancer Center, Houston
- START San Antonio, San Antonio
Се регрутираФаза 1/2
Возраст 18 и постари · Сите полови · Ажурирано 16.9.2026 · NCT05786924A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
- Ascension Seton Spclty Care Ctr, Austin
- Texas Oncology, Austin
- University of Texas Southwestern Medical Center, Dallas
- и уште 2
Се регрутираФаза 3
Возраст 18 и постари · Сите полови · Ажурирано 15.9.2026 · NCT07284849Од ClinicalTrials.gov, податоци преземени 6.10.2026. Секоја студија ги поставува своите услови за вклучување; тимот на студијата одлучува кој може да учествува.